Want to see FR:ALNEV full AI Analyst Report?
ALNEV Stock Chart & Stats
€0.01
-€0.06(-6.03%)
At close: 4:00 PM EST
€0.01
-€0.06(-6.03%)
Day’s Range― - ―
52-Week Range€0.17 - €4,200.00
Previous CloseN/A
Volume950.00
Average Volume (3M)40.21K
Market Cap
€222.56K
Enterprise Value€3.26B
Total Cash (Recent Filing)€571.79K
Total Debt (Recent Filing)€537.20K
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-51100.07
Shares Outstanding1,222,855
10 Day Avg. Volume42,841
30 Day Avg. Volume40,207
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low reported leverage reduces refinancing pressure and leaves more financial flexibility than a heavily indebted biotechnology company would have. This can help Neovacs preserve strategic options and absorb operating volatility, although it does not eliminate the need to fund ongoing losses.
Improving Cash-Burn TrendThe improvement in cash-burn pace and less-negative free cash flow in 2025 indicate some progress in financial control. If sustained, this could extend the company’s funding runway and reduce the speed at which external capital is required, even though operations remain cash-consuming.
Kinoid Immunotherapy PlatformThe Kinoid platform gives Neovacs a defined technology base focused on durable immune responses in chronic inflammatory and autoimmune diseases. A platform approach may support multiple development opportunities across indications, rather than relying on a single narrowly targeted candidate.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the current business has not reached an economically sustainable scale. Continued losses can erode shareholder capital, constrain investment in research programs, and make future success increasingly dependent on financing or commercial milestones.
Revenue Decline And VolatilitySharp revenue contraction and inconsistent sales indicate limited commercial traction and weak revenue visibility. This makes it harder to fund research internally, plan spending confidently, or demonstrate a durable commercial model over the next several quarters.
Ongoing External Funding NeedNegative operating and free cash flow across every reported year means Neovacs continues to consume cash rather than finance itself. Unless revenue improves materially or costs fall, the company will likely need external capital over time, creating ongoing funding dependence.
Neovacs SA News
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.17 and its highest was €4200.00 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €222.56K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 22, 2026 which is in 10 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Mar 30, 2026. The company reported -€0.066 earnings per share for the quarter.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 1,222,855 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€0.066 in its last earnings report. Following the earnings report the stock price went down -11.446%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.